BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/6/2025 3:09:35 AM | Browse: 1 | Download: 11
 |
Received |
|
2025-02-28 06:52 |
|
Peer-Review Started |
|
2025-02-28 06:53 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-03-13 03:16 |
|
Revised |
|
2025-03-21 12:21 |
|
Second Decision |
|
2025-04-16 02:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-04-16 04:52 |
|
Articles in Press |
|
2025-04-16 04:52 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-05-30 09:25 |
|
Publish the Manuscript Online |
|
2025-06-06 03:09 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Targeting the NAD+/SIRT1 axis: A metabolic strategy to overcome oxaliplatin resistance in colorectal cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Md Sadique Hussain, Vikash Jakhmola, Kavita Goyal, Arcot Rekha, Ayesha Sultana, Haider Ali and Gaurav Gupta |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Md Sadique Hussain, Assistant Professor, PhD, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Prem Nagar, Dehra Dun 248007, Uttarākhand, India. sadiquehussain007@gmail.com |
| Key Words |
SIRT1; Glycolysis; Drug resistance; Colorectal cancer; Chemotherapy |
| Core Tip |
Oxaliplatin resistance remains a major clinical challenge in colorectal cancer (CRC). This study underscores the critical role of the NAD+/SIRT1 axis in driving metabolic reprogramming that facilitates resistance. Oxaliplatin-induced DNA damage activates PARP, leading to NAD+ depletion and subsequent downregulation of SIRT1. This reduction in SIRT1 expression enhances glycolysis, marked by upregulation of PKM2 and LDHA. Notable, restoration of SIRT1 reverses resistance, while glycolysis inhibition sensitizes CRC cells to oxaliplatin. These findings suggest that targeting the NAD+/SIRT1 pathway, through SIRT1 agonists and glycolysis inhibitors, offers a promising metabolic strategy to overcome chemoresistance and improve therapeutic outcomes in CRC patients. |
| Publish Date |
2025-06-06 03:09 |
| Citation |
<p>Hussain MS, Jakhmola V, Goyal K, Rekha A, Sultana A, Ali H, Gupta G. Targeting the NAD+/SIRT1 axis: A metabolic strategy to overcome oxaliplatin resistance in colorectal cancer. <i>World J Gastroenterol</i> 2025; 31(21): 106530</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i21/106530.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i21.106530 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
